SNORA55: A Potential Drug Target and Biomarker for Neurological Diseases

Target Name: SNORA55

NCBI ID: G677834

SNORA55

Other Name(s): Small nucleolar RNA, H/ACA box 55 | small nucleolar RNA, H/ACA box 55 | ACA55 | ACA55 snoRNA

SNORA55: A Potential Drug Target and Biomarker for Neurological Diseases

SNORA55, also known as H/ACA box 55, is a small non-coding RNA molecule that is expressed in various cell types of the human body. It is located within the H/ACA box gene, which encodes for a protein known as HACE1. HACE1 is a nuclear protein that is involved in the process of chromatin remodeling, which is the process by which the DNA in our cells is organized and structured in a specific way to ensure the proper functioning of our genes.

SNORA55 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its unique structure and function have made it an attractive target for researchers to study, and a potential therapy for these diseases.

One of the key reasons why SNORA55 has potential as a drug target is its unique expression pattern. SNORA55 is primarily expressed in the brain, and its levels are highly correlated with the levels of the HACE1 protein. This suggests that SNORA55 may play a role in the regulation of the HACE1 gene, and potentially, the regulation of neural development and function.

Additionally, SNORA55 has been shown to play a role in the development and progression of various neurological diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and the development of neurodegeneration, and SNORA55 has been shown to be involved in the regulation of the neurodegenerate process.

Another potential reason why SNORA55 may be a useful biomarker for these diseases is its expression pattern in different brain regions. Studies have shown that SNORA55 is expressed in various brain regions, including the prefrontal cortex, the basal ganglia, and the entorhinal cortex. This suggests that SNORA55 may be a useful biomarker for the diagnosis and progression of neurodegenerative diseases, as changes in the expression of SNORA55 may be indicative of the progression of the disease.

In addition to its potential as a drug target and biomarker, SNORA55 has also been shown to have a role in the regulation of cellular processes that are important for brain function. For example, studies have shown that SNORA55 is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. Additionally, SNORA55 has been shown to be involved in the regulation of neurotrophic factor (NTF), which is a protein that supports the survival and growth of nerve cells.

Overall, SNORA55 is a small non-coding RNA molecule that has a unique structure and function. Its expression pattern and its involvement in the regulation of various cellular processes make it an attractive target for research and potential therapeutic intervention. As research continues to advance, it is likely that SNORA55 will be found to have even more potential as a drug target and biomarker for the treatment of various neurological diseases.

Protein Name: Small Nucleolar RNA, H/ACA Box 55

The "SNORA55 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA55 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets